Important: Please read all instructions below before completing FIS 2288.

Section 2212c of Public Act 218 of 1956, MCL 500.2212c, requires the use of a standard prior authorization form when a policy, certificate or contract requires prior authorization for prescription drug benefits.

A standard form, FIS 2288, is being made available to simplify exchanges of information between prescribers and health insurers as part of the process of requesting prescription drug prior authorization. This form will be updated periodically and the form number and most recent revision date are displayed in the top left hand corner.

- Prior authorization requests are defined as requests for pre-approval from an insurer for specified medications or quantities of medications before they are dispensed.
- Prescriber means the term as defined in section 17708 of the Public Health Code, 1978 PA 368, MCL 333.17708.
- Prescription drug means the term as defined in section 17708 of the Public Health Code, 1978 PA 368, MCL 333.17708.
- This form is made available for use by prescribers to initiate a prior authorization request.
- Insurers may request additional information or clarification needed to process a prior authorization request. The prior authorization is not considered granted if the prescriber fails to submit the additional information within 72 hours after the date and time of the original submission of a properly completed prior authorization request.
- In order to designate a prior authorization request for expedited review, a prescriber must certify that applying the 15-day standard review period may seriously jeopardize the life and health of the patient or the patient’s ability to regain maximum function.
Michigan Prior Authorization
Request Form for Prescription Drugs  Fax: 858-790-7100

☐ Expedited Review Request: I hereby certify that a standard review period may seriously jeopardize the life or health of the patient or the patient's ability to regain maximum function.
Physician's Direct Contact Phone Number ( ) - _______ Initials: ___________

A) Reason for Request
☐ Initial Authorization Request  ☐ Renewal Request  ☐ DAW

B) Patient Demographics
Is patient hospitalized:  ☐ Yes  ☐ No
Patient Name: ___________________________ DOB: __________________
Patient Health Plan ID: __________________________
☐ Male  ☐ Female

C) Pharmacy Insurance Plan
☐ Priority  ☐ Magellan  ☐ Blue Cross Blue Shield of Michigan  ☐ HAP  ☐ ___________
☐ Total Health Care  ☐ Blue Care Network  ☐ HealthPlus of Michigan  ☐ Meridian Health Plan

D) Prescriber Information
Prescriber Name: ___________________________ NPI: ___________ Specialty: ___________
DEA (required for controlled substance requests only): __________________________
Contact Name: ___________________________ Contact Phone: ___________ Contact Fax: ___________
Health Plan Provider ID (if accessible): __________________________

E) Pharmacy Information (optional)
Pharmacy Name_________________________ Pharmacy Telephone________________________

F) Requested Prescription Drug Information
Drug Name: ___________________________ Strength: ___________
Dosing Schedule: ___________________________ Duration: ___________
Diagnosis (specific) with ICD#: ___________________________
Place of infusion / injection (if applicable): ___________________________
Facility Provider ID / NPI: ___________________________
Has the patient already started the medication? _______ Yes _______ No  If so, when? ___________
G) **Rationale for Prior Authorization** (e.g., information such as history of present illness, past medical history, current medications, etc.; you may also attach chart notes to support your request if you believe they will assist with the review process)

H) **Failed/Contraindicated Therapies**

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Strength</th>
<th>Dosing Schedule</th>
<th>Duration</th>
<th>Adverse Event/Specific Failure</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

I) **Other Pertinent Information** (Optional - to be filled out if other information is necessary such as relevant diagnostic labs, measures of response to treatment, etc.) Please refer to plan’s website for additional information that may be necessary for review. Please note that sending this form with insufficient clinical information may result in extended review period or adverse determination.

I represent to the best of my knowledge and belief that the information provided is true, complete and fully disclosed. A person may be committing insurance fraud if false or deceptive information with the intent to defraud is provided.

Physician’s Name: ____________________________________________

Physician’s Signature: ________________________________________

Date: ______________

PA 218 of 1956 as amended requires the use of a standard prior authorization form by prescribers when a patient’s health plan requires prior authorization for prescription drug benefits.

*For Health Plan Use Only*

<table>
<thead>
<tr>
<th>Request Date:</th>
<th>LOB:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approved:</td>
<td>Denied:</td>
</tr>
<tr>
<td>Approved By:</td>
<td>Denied By:</td>
</tr>
<tr>
<td>Effective Date:</td>
<td>Reason for Denial:</td>
</tr>
<tr>
<td>Additional Comments:</td>
<td></td>
</tr>
</tbody>
</table>

**Michigan Department of Insurance and Financial Services**

DIF is an equal opportunity employer/program.
Auxiliary aids, services and other reasonable accommodations are available upon request to individuals with disabilities.
Visit DIF online at: www.michigan.gov/difs Phone DIF toll-free at: 877-999-6442
UNIVERSITY OF MICHIGAN – HUMIRA® (adalimumab)

Some of the information needed to make a determination for coverage is not specifically requested on the Michigan Prior Authorization Request Form for Prescription Drugs. To avoid delays in reviewing your request, please make sure to include all of the following information.

<table>
<thead>
<tr>
<th>Answer Questions 1 Through 3 for All Patients and the Questions Related to Your Patient’s Diagnosis. (Renewal Patients for Ulcerative Colitis, Answer Only Question 26.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Has the patient been evaluated for active infection before treatment, and will the patient be monitored for signs and symptoms of infection during and after treatment with Humira?</td>
</tr>
<tr>
<td>2. Will the patient be evaluated for latent tuberculosis before use and during treatment with Humira?</td>
</tr>
<tr>
<td>3. Will the patient receive concurrent live vaccines, Kineret (anakinra), or other biologic treatment options during treatment with Humira?</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Arthritis, Rheumatoid or Psoriatic (Also Answer Questions 4 - 7)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4. Is Humira therapy being prescribed or recommended by a dermatologist or rheumatologist and will the patient be monitored for potential complications of Humira therapy (i.e., lymphoma and other malignancies, new or worsening congestive heart failure or allergic reaction)?</td>
</tr>
<tr>
<td>5. Is the patient age 18 years or older?</td>
</tr>
<tr>
<td>6. Does the patient have a diagnosis of (please circle applicable diagnosis)</td>
</tr>
<tr>
<td>• moderately to severely active rheumatoid arthritis; or</td>
</tr>
<tr>
<td>• active psoriatic arthritis?</td>
</tr>
<tr>
<td>7. Has the patient tried and failed, had inadequate response, or is contraindicated or unable to tolerate non-biologic disease modifying antirheumatic drugs (DMARDs) (e.g., methotrexate)?</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Juvenile Idiopathic Arthritis (JIA) (Also Answer Questions 8 - 10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8. Is Humira therapy being prescribed or recommended by a rheumatologist and will the patient be monitored for potential complications of Humira therapy (i.e., lymphoma and other malignancies, new or worsening congestive heart failure or allergic reaction)?</td>
</tr>
<tr>
<td>9. Does the patient have a diagnosis of moderately to severely active polyarticular juvenile idiopathic arthritis and is the patient 2 years of age or older?</td>
</tr>
<tr>
<td>10. Will the patient be evaluated for lymphoma and other malignancies during and after treatment with Humira?</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ankylosing Spondylitis (Also Answer Questions 11 - 14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11. Is Humira therapy being prescribed or recommended by a rheumatologist and will the patient be monitored for potential complications of Humira therapy (i.e., lymphoma and other malignancies, new or worsening congestive heart failure or allergic reaction)?</td>
</tr>
<tr>
<td>12. Is the patient age 18 years or older?</td>
</tr>
<tr>
<td>13. Does the patient have a diagnosis of active ankylosing spondylitis?</td>
</tr>
<tr>
<td>14. Has the patient tried and failed at least two (2) non-steroidal anti-inflammatory drugs (NSAIDs) OR is the use of NSAIDs contraindicated?</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Crohn’s Disease (Also Answer Questions 15 - 18)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15. Is Humira therapy being prescribed or recommended by a gastroenterologist and will the patient be monitored for potential complications of Humira therapy (i.e., lymphoma and other malignancies, new or worsening congestive heart failure or allergic reaction)?</td>
</tr>
<tr>
<td>16. Does the patient have a diagnosis of moderately to severely active Crohn’s disease?</td>
</tr>
<tr>
<td>17. Is the patient age 6 years or older?</td>
</tr>
<tr>
<td>18. Has the patient tried and failed, had inadequate response, or is contraindicated or unable to tolerate at least one first line agent for Crohn’s disease such as corticosteroids or immunosuppressants (e.g., methotrexate)?</td>
</tr>
</tbody>
</table>

Questions continue on page 2.
PLAQUE PSORIASIS (ALSO ANSWER QUESTIONS 19 - 22)

19. Is Humira therapy being prescribed or recommended by a rheumatologist or dermatologist and will the patient be monitored for potential complications of Humira therapy (i.e., lymphoma and other malignancies, new or worsening congestive heart failure or allergic reaction)?
   - Y N

20. Is the patient age 18 years or older?
   - Y N

21. Does the patient have a diagnosis of moderate to severe plaque psoriasis?
   - Y N

22. Is the patient a candidate for systemic therapy or phototherapy?
   - Y N

ULCERATIVE COLITIS INITIAL (ALSO ANSWER QUESTIONS 23 - 25)

23. Is Humira therapy being prescribed or recommended by a gastroenterologist and will the patient be monitored for potential complications of Humira therapy (i.e., lymphoma and other malignancies, new or worsening congestive heart failure or allergic reaction)?
   - Y N

24. Is the patient age 18 years or older?
   - Y N

25. Does the patient have a diagnosis of moderately to severely active ulcerative colitis and has had an inadequate response to immunosuppressants (e.g., corticosteroids, azathioprine, 6-mercaptopurine)?
   - Y N

ULCERATIVE COLITIS RENEWALS ONLY (ANSWER QUESTION 26)

26. RENEWAL Only (after 8 weeks): Has the patient shown evidence of clinical remission?
   - Y N

HIDRADENTIS SUPPURATIVA (PATIENTS WITH HURLEY STAGE II-III DISEASE) (ANSWER QUESTION 27-31)

27. Is Humira therapy being prescribed or recommended by or in consultation with a dermatologist and will the patient be monitored for potential complications of Humira therapy (i.e., lymphoma and other malignancies, new or worsening congestive heart failure or allergic reaction)?
   - Y N

28. Has the patient failed to show significant improvement with systemic antibiotic therapy of at least 4 months in duration?
   - Y N

29. Will the patient be on concurrent therapy with Kineret (anakinra), Orencia (abatacept), Rituxan (rituximab), or another TNF inhibitor (Enbrel, Cimzia, Remicade, Simponi, or Simponi Aria) or another biological agent?
   - Y N

30. Is the patient age 15 years or older?
   - Y N

31. Does the patient have a diagnosis of Hidradentis Suppurativa (Hurley State II-III)
   - Y N

HIDRADENTIS SUPPURATIVA (PATIENTS WITH HURLEY STAGE II-III DISEASE) RENEWALS ONLY (ANSWER QUESTION 32-33)

32. Does the patient have a diagnosis of Hidradentis Suppurativa (Hurley State II-III disease)?
   - Y N

33. Will the patient be on concurrent therapy with Kineret (anakinra), Orencia (abatacept), Rituxan (rituximab), or another TNF inhibitor (Enbrel, Cimzia, Remicade, Simponi, or Simponi Aria) or another biological agent?
   - Y N

FOR PATIENTS NON-INFECTIONS INTERMEDIATE, POSTERIOR AND PANUVEITIS (ANSWER QUESTIONS 34-37).

34. Does patient have diagnosis of non-infectious intermediate, posterior and panuveitis?
   - Y N

35. Is Humira being prescribed or in consultation with an ophthalmologist?
   - Y N

36. Is patient 18 years of age or older?
   - Y N

37. Does patient have isolated anterior uveitis?
   - Y N

FOR PATIENTS NON-INFECTIONS INTERMEDIATE, POSTERTERIOR AND PANUVEITIS – (RENEWALS ONLY ANSWER QUESTIONS 38-40).

38. Has the condition improved or stabilized with Humira?
   - Y N

39. Is the patient free from active infection (including tuberculosis and hepatitis B (HBV))?
   - Y N

40. Is Humira being used in combination with any other biologic agent?
   - Y N

Revised November, 2016